Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 3/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130681 | 0.78 | TEAD1 (0.38) | TEAD1BCL9CTNNB1EPHX2KDM1A | |
| SCHEMBL10127510 | 0.78 | CHRM4 (0.44) | TEAD1EPHX2 | |
| SCHEMBL4350210 | 0.76 | MAOB (0.48) | TEAD1BCL9CTNNB1KDM1AUTS2R | |
| SCHEMBL649739 | 0.76 | UTS2R (0.51) | TEAD1UTS2R | |
| SCHEMBL651149 | 0.76 | UTS2R (0.56) | TEAD1UTS2R | |
| SCHEMBL647679 | 0.75 | SLC6A4 (0.46) | TEAD1BCL9CTNNB1EPHX2KDM1A | |
| SCHEMBL648264 | 0.74 | SLC6A4 (0.45) | TEAD1BCL9CTNNB1KDM1AAR | |
| Hydrochloric Acid SCHEMBL648678 | 0.74 | SLC6A4 (0.45) | TEAD1BCL9CTNNB1EPHX2KDM1A | |
| SCHEMBL651078 | 0.74 | RAB9A (0.46) | TEAD1BCL9CTNNB1KDM1AAR | |
| Hydrochloric Acid SCHEMBL647344 | 0.74 | SLC6A4 (0.44) | TEAD1BCL9CTNNB1KDM1AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | TEAD1 2575/4885BCL9 2443/4885CTNNB1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.